Chronic lung allograft dysfunction ends most lung transplants after the first year, and spirometry only flags it once the airway remodelling is permanent. A prospective Melbourne cohort of 69 recipients tried to move that window earlier, running multi-omics profiling on surveillance bronchoalveolar lavage out to 30 months post-transplant. What separated the 13 patients who later developed CLAD was not infection. It was an endothelial glycocalyx and neutrophil-recruitment prog

Deciding when to stop immunosuppression in ANCA-associated vasculitis (AAV) is guesswork more often than anyone treating it would like. C-reactive protein (CRP) and ANCA titer stay elevated in plenty of patients who are clinically quiet, so therapy drags on and infection risk climbs with it. A clinical proteomics study in Nature Communications went at that gap directly: plasma from 163 people was profiled by DIA LC-MS/MS, and the seven-protein panel that came out of it told a

Risk calculators built from age, blood pressure, and a lipid panel still miss many people who develop disease within a decade. A multi-omics analysis of 23,776 UK Biobank participants tested how far plasma profiling closes that gap, measuring 159 NMR metabolites and 2,923 Olink protein targets in the same individuals across 17 incident diseases. Adding omics improved prediction for every endpoint. The more useful result is which layer did the work. Key Takeaways Plasma proteo

Coronary artery calcification usually shows up on a CT calcium scan: radiation, a scanner slot, and a cost most primary-care patients never absorb. A blood test would change that math. Clinical proteomics offers one route. Cui and Liu screened serum by data-independent acquisition mass spectrometry and pulled a three-protein signature out of a crowded plasma background. Their two-stage case-control design, 60 subjects for discovery and 260 for validation, flags SMOC1, HSP90B1

Parkinson's disease is usually caught only after most dopaminergic neurons are gone, leaving a narrow window for treatments that might slow it. A January 2026 study in PLOS ONE asked a sharper question: could a multi-omics fingerprint from blood and cerebrospinal fluid flag the disease earlier? Wei Liu and colleagues pulled DNA methylation, gene expression, and cerebrospinal fluid proteomics from 305 participants in the Parkinson's Progression Markers Initiative, then stacked